1395281-82-9

Basic information

• Product Name: methyl 6-(2,6-difluoro-4-(3-fluorooxetan-3-yl)phenyl)-5-fluoropicolinate
• Synonyms: methyl 6-(2,6-difluoro-4-(3-fluorooxetan-3-yl)phenyl)-5-fluoropicolinate
• CAS NO: 1395281-82-9
• Molecular Weight: 341.262
• Mol File: 1395281-82-9.mol

Chemical Properties

• CAS DataBase Reference: methyl 6-(2,6-difluoro-4-(3-fluorooxetan-3-yl)phenyl)-5-fluoropicolinate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 6-(2,6-difluoro-4-(3-fluorooxetan-3-yl)phenyl)-5-fluoropicolinate(1395281-82-9)
• EPA Substance Registry System: methyl 6-(2,6-difluoro-4-(3-fluorooxetan-3-yl)phenyl)-5-fluoropicolinate(1395281-82-9)

Safety Data

• Hazardous Substances Data: 1395281-82-9(Hazardous Substances Data)

Upstream product

• 1395281-70-5 methyl 6-(2,6-difluoro-4-(3-hydroxyoxetan-3-yl)phenyl)-5-fluoropicolinate 
• 1395281-67-0 3-(3,5-difluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)oxetan-3-ol 
• 1395281-64-7 3-(3,5-difluorophenyl)oxetan-3-ol 
• 461-96-1 3,5-difluorobromobenzene 
• 1210419-26-3 methyl 6-bromo-5-fluoropyridine-2-carboxylate 
• 1052714-46-1 6-bromo-5-fluoro-pyridine-2-carboxylic acid 
• 374633-36-0 2-bromo-3-fluoro-6-methylpyridine 

Downstream Products

• 1395281-85-2 6-(2,6-difluoro-4-(3-fluorooxetan-3-yl)phenyl)-5-fluoropicolinic acid 

Relevant articles and documents

N-(3-PYRIDYL) BIARYLAMIDES AS KINASE INHIBITORS

The present invention provides a compound of formula (I): as described herein, and pharmaceutically acceptable salts, enantiomers, rotamers, tautomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by PIM kinase using the compounds of Formula (I), and pharmaceutical compositions comprising such compounds.

NOVEL KINASE INHIBITORS

The present invention provides compounds of Formula I: and related compounds as further described herein, and pharmaceutical compositions comprising these compounds. The invention further provides methods to use these compounds and compositions for treating disorders associated with undesired levels of Pim kinase activity, including cancers and autoimmune disorders.

TETRASUBSTITUTED CYCLOHEXYL COMPOUNDS AS KINASE INHIBITORS

The present invention provides a compound of formula (I): as further described herein, and pharmaceutically acceptable salts, enantiomers, rotamers, tautomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by PIM kinase using the compounds of Formula I, and pharmaceutical compositions comprising such compounds.